Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Tuesday, Benzinga reports. The brokerage currently has a $8.00 price target on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Hold and a consensus target price of $9.33.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $2.37 on Tuesday. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The firm has a market capitalization of $448.88 million, a P/E ratio of -1.12 and a beta of 0.89. The company’s 50-day moving average is $2.32 and its 200 day moving average is $2.07.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the same period last year, the company earned ($0.76) earnings per share. Research analysts anticipate that Esperion Therapeutics will post -0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Susquehanna Fundamental Investments LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $446,000. CVI Holdings LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $37,000. SG Americas Securities LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $69,000. Boomfish Wealth Group LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $80,000. Finally, Mesirow Financial Investment Management Inc. purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $54,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.